Key Insights

Highlights

Success Rate

91% trial completion (above average)

Treatment Research

20 treatments under study, led by Cyclophosphamide

Published Results

23 trials with published results (14%)

Research Leaders

20 sponsors active, led by National Heart, Lung, and Blood Institute (NHLBI)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

5.9%

10 terminated out of 170 trials

Success Rate

90.7%

+4.0% vs benchmark

Late-Stage Pipeline

14%

23 trials in Phase 3/4

Results Transparency

24%

23 of 97 completed with results

Key Signals

23 with results91% success

Data Visualizations

Phase Distribution

118Total
Not Applicable (37)
Early Phase 1 (4)
Phase 1 (19)
Phase 1/2 (11)
Phase 2 (21)
Phase 2/3 (3)
Phase 3 (19)
Phase 4 (4)

Trial Status

Completed97
Unknown22
Recruiting15
Terminated10
Withdrawn10
Active Not Recruiting6

Trial Success Rate

90.7%

Benchmark: 86.6%

Based on 97 completed trials

Clinical Trials (170)

Showing 20 of 20 trials
NCT01287000Active Not Recruiting

Gulf Long-Term Follow-Up Study

NCT06487247Not ApplicableRecruiting

HEME Home Transfusion Program

NCT04450927Enrolling By Invitation

Data Collection of Standard Care and Evaluation of NHLBI Patients and Donors

NCT05982249Not ApplicableCompletedPrimary

Hypnosis and Virtual Reality in Bone Marrow Examination

NCT05982262Not ApplicableCompletedPrimary

Naturopathic-pharmacological Consultation in Hematology

NCT06477783Recruiting

Study on the Clinical Efficacy of Teclistamab and Talquetamab

NCT06613425Phase 4CompletedPrimary

Clinical Study of Combined Platelet Transfusion

NCT07679958Not ApplicableNot Yet RecruitingPrimary

Immersive Virtual Reality Applied to Therapeutic Physical Exercise in Cellular Therapy

NCT07023692Not ApplicableEnrolling By Invitation

Visual and Auditory Distraction for the Relief of Pain and Anxiety

NCT07387354Phase 1/2Withdrawn

Pacritinib With Aza for Upfront Myelodysplastic Syndrome

NCT05150561Active Not RecruitingPrimary

Muscle Dysfunction in Patients With Haematological Diseases

NCT04208529Phase 3Enrolling By Invitation

A Long-term Follow-up Study in Participants Who Received CTX001

NCT07701889Phase 1Not Yet RecruitingPrimary

Bispecific CD19/CD20-Targeted Chimeric Antigen Receptor (CAR) Modified T Cells With 4-1BB and Mutated CD28 Costimulatory Domains in Patients With Relapsed or Refractory CD19+ Hematologic Malignancies

NCT05356195Phase 3Active Not Recruiting

Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)

NCT02343965Not ApplicableCompletedPrimary

The Impact of the Practice of Touch-massage on the Anxiety of Patients With Hematological Disorders Hospitalized in a Protective Environment, a Randomized, Controlled Study

NCT06795815Not ApplicableRecruiting

The Implementation of the Go Wish Game to Promote Advance Care Planning in Onco- Hematologic Disease

NCT06187831Completed

Bleeding Events Before vs After Lowering Departmental Platelet Transfusion Trigger

NCT05414045Not ApplicableRecruiting

Autologous Testicular Tissue Transplantation

NCT03578367Phase 2Completed

Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.

NCT03030248Phase 2Completed

Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients

Scroll to load more

Research Network

Common Treatments

  • Cyclophosphamide7
  • Busulfan6
  • Ctx0014
  • Rd1302 Cell Infusion4
  • Fludarabine4

Active Sponsors

  • National Heart, Lung, and Blood Institute (NHLBI)23
  • Universitaire Ziekenhuizen KU Leuven5
  • Copenhagen University Hospital, Rigshospitalet5
  • Vertex Pharmaceuticals Inc.4
  • Stanford University4

Top Investigators

Related Conditions

  • Neoplasms15
  • Leukemia14
  • Multiple Myeloma12
  • Anemia Sickle Cell10
  • Hemoglobinopathies10

Activity Timeline